Emergent BioSolutions | EBS - 贸易债权人



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 437.5M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


贸易债权人 更改 日
Acadia Pharmaceuticals USD 10.9M 10.84M 2025-12
Akebia Therapeutics USD 21.18M 11.1M 2025-12
ALKERMES USD 107.95M 39.95M 2025-12
Alnylam Pharmaceuticals USD 115.72M 1.87M 2025-12
Amarin USD 45.36M 8.64M 2025-12
ANI Pharmaceuticals USD 62.58M 7.21M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Coherus Biosciences USD 9.91M 14.98M 2025-12
Emergent BioSolutions USD 112.2M 500K 2023-12
Exelixis USD 29.62M 4.27M 2025-12
Glaxosmithkline GBP 20.72B 346.14M 2025-12
Heron Therapeutics USD 8.99M 3.02M 2025-12
Ionis Pharmaceuticals USD 14.33M 8.47M 2025-09
Ironwood Pharmaceuticals USD 1.61M 224K 2025-09
Lexicon Pharmaceuticals USD 3.08M 714K 2025-12
Lonza CHF 471M 3M 2024-12
Merck USD 4.15B 102M 2025-09
Moderna USD 317M 50M 2025-12
Myriad Genetics USD 30M 1.8M 2025-12
Nektar Therapeutics USD 10.77M 4.79M 2025-12
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Pacira USD 15.15M 2.54M 2025-12
Pfizer USD 5.02B 142M 2025-09
PTC Therapeutics USD 45.49M 8.87M 2025-12
Sanofi EUR 22.93B 927M 2025-12
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
United Therapeutics USD 7.1M 460.9M 2025-12
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12
Xoma USD 2.65M 1.52M 2025-09